Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Candesartan Cilexetil

FDA-approved product (tablet, oral), marketed as Atacand, Candesartan Cilexetil.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Candesartan Cilexetil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angina pectoris
  • Congestive heart failure
  • Diabetes mellitus
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Angiotensin ii receptor blockers (arbs), plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Candesartan Cilexetil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Candesartan Cilexetil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission.

    NCT07513883 · start 2026-03-16

    Registered record
    Registry ID
    NCT07513883
    Conditions
    Heart Failure
    Interventions
    Down-titration; Continuation of guideline-directed heart failure therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-03-16
    Completion
    2028-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionDown-titration; Continuation of guideline-directed heart failure therapy
    PhasePhase 4
    Registry statusRecruiting

  • To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia

    NCT06646354 · start 2025-04-22

    Registered record
    Registry ID
    NCT06646354
    Conditions
    Hypertension; Primary Hypercholesterolaemia
    Interventions
    Ezetimibe/Rosuvastatin/Candesartan/Amlodipine; Candesartan/Amlodipine; Candesartan/Rosuvastatin/Ezetimibe
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Enrolling by invitation
    Start
    2025-04-22
    Completion
    2028-12-31
    Enrolment
    125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Primary Hypercholesterolaemia
    InterventionEzetimibe/Rosuvastatin/Candesartan/Amlodipine; Candesartan/Amlodipine; Candesartan/Rosuvastatin/Ezetimibe
    PhasePhase 3
    Registry statusEnrolling by invitation

  • Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury

    NCT05826912 · start 2024-08-01

    Registered record
    Registry ID
    NCT05826912
    Conditions
    Traumatic Brain Injury
    Interventions
    Atorvastatin Calcium; Minocycline Hydrochloride; Candesartan Cilexetil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Enrolling by invitation
    Start
    2024-08-01
    Completion
    2029-08-31
    Enrolment
    672

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTraumatic Brain Injury
    InterventionAtorvastatin Calcium; Minocycline Hydrochloride; Candesartan Cilexetil; Placebo
    PhasePhase 2
    Registry statusEnrolling by invitation

  • Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)

    NCT05321875 · start 2022-06-02

    Registered record
    Registry ID
    NCT05321875
    Conditions
    Cardiomyopathy, Dilated
    Interventions
    Candesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-06-02
    Completion
    2026-06-02
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiomyopathy, Dilated
    InterventionCandesartan
    PhasePhase 3
    Registry statusRecruiting

  • Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension

    NCT06212648 · start 2022-03-25

    Registered record
    Registry ID
    NCT06212648
    Conditions
    Hypertension; Essential Hypertension
    Interventions
    SPC1001 High; SPC1001 Mid1; SPC1001 Mid2; SPC1001 Low; SPC3001; SPC4001; SPC4002; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-03-25
    Completion
    2023-01-27
    Enrolment
    253

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Essential Hypertension
    InterventionSPC1001 High; SPC1001 Mid1; SPC1001 Mid2; SPC1001 Low +4 more
    PhasePhase 2
    Registry statusCompleted

  • Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD

    NCT05169021 · start 2021-12-31

    Registered record
    Registry ID
    NCT05169021
    Conditions
    Cerebral Small Vessel Diseases; Stroke
    Interventions
    Amlodipine folic acid 5.8mg+intensive antihypertensive therapy; Amlodipine folic acid 5.8mg+standard antihypertensive therapy; Amlodipine+intensive antihypertensive therapy; Amlodipine+standard antihypertensive therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2021-12-31
    Completion
    2028-12-31
    Enrolment
    15,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebral Small Vessel Diseases; Stroke
    InterventionAmlodipine folic acid 5.8mg+intensive antihypertensive therapy; Amlodipine folic acid 5.8mg+standard antihypertensive therapy; Amlodipine+intensive antihypertensive therapy; Amlodipine+standard antihypertensive therapy
    PhasePhase 4
    Registry statusNot yet recruiting

  • Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

    NCT04606563 · start 2020-10-09

    Registered record
    Registry ID
    NCT04606563
    Conditions
    Covid19; SARS-CoV Infection
    Interventions
    Losartan; Valsartan; Azilsartan; Candesartan; Eprosartan; Irbesartan; Olmesartan; Telmisartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2020-10-09
    Completion
    2022-04-22
    Enrolment
    341

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; SARS-CoV Infection
    InterventionLosartan; Valsartan; Azilsartan; Candesartan +4 more
    PhasePhase 3
    Registry statusTerminated

  • Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)

    NCT04351724 · start 2020-04-16

    Registered record
    Registry ID
    NCT04351724
    Conditions
    COVID-19
    Interventions
    Chloroquine or Hydroxychloroquine; Lopinavir/Ritonavir; Best standard of care; Rivaroxaban; Thromboprophylaxis; Candesartan; non-RAS blocking antihypertensives; Remdesivir; Asunercept 400mg; Asunercept 100mg; Asunercept 25mg; Pentaglobin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2020-04-16
    Completion
    2022-03-31
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionChloroquine or Hydroxychloroquine; Lopinavir/Ritonavir; Best standard of care; Rivaroxaban +8 more
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • CandeSpartan Study. Candesartan Spanish Response-prediction and Tolerability Study

    NCT04138316 · start 2020-01-02

    Registered record
    Registry ID
    NCT04138316
    Conditions
    Migraine; Head Pain
    Interventions
    Candesartan
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-01-02
    Completion
    2022-12-16
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Head Pain
    InterventionCandesartan
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension

    NCT03640312 · start 2019-08-30

    Registered record
    Registry ID
    NCT03640312
    Conditions
    Hypertension
    Interventions
    QUARTET LDQT; Candesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-08-30
    Completion
    2024-07-31
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionQUARTET LDQT; Candesartan
    PhasePhase 2
    Registry statusCompleted

  • Statins and ARBs on Rheumatoid Activity

    NCT03770702 · start 2018-10-01

    Registered record
    Registry ID
    NCT03770702
    Conditions
    Rheumatoid Arthritis
    Interventions
    Angiotensin receptor blockers; Statins
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2018-10-01
    Completion
    2026-12-01
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionAngiotensin receptor blockers; Statins
    PhasePhase 3
    Registry statusRecruiting

  • Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets

    NCT03847506 · start 2018-07-05

    Registered record
    Registry ID
    NCT03847506
    Conditions
    Hypertension, Hyperlipidemia
    Interventions
    Ezetimibe/Rosuvastatin; Candesartan cilexetil/Amlodipine besylate; Candesartan cilexetil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-07-05
    Completion
    2020-12-02
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Hyperlipidemia
    InterventionEzetimibe/Rosuvastatin; Candesartan cilexetil/Amlodipine besylate; Candesartan cilexetil
    PhasePhase 4
    Registry statusCompleted

  • A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

    NCT04521023 · start 2017-09-20

    Registered record
    Registry ID
    NCT04521023
    Conditions
    Hypertension
    Interventions
    Cantabell Tab; Candemore Plus Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-09-20
    Completion
    2020-06-03
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionCantabell Tab; Candemore Plus Tab
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control

    NCT02521246 · start 2016-11

    Registered record
    Registry ID
    NCT02521246
    Conditions
    Essential Arterial Hypertension
    Interventions
    Candesartan + Chlorthalidone; Candesartan + Chlorthalidone; Losartan+hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2016-11
    Completion
    2017-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Arterial Hypertension
    InterventionCandesartan + Chlorthalidone; Candesartan + Chlorthalidone; Losartan+hydrochlorothiazide
    PhasePhase 3
    Registry statusWithdrawn

  • Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

    NCT02651870 · start 2015-04-22

    Registered record
    Registry ID
    NCT02651870
    Conditions
    Hypertension
    Interventions
    Candesartan 16mg; Amlodipine 5mg; Amlodipine 10mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-04-22
    Completion
    2016-02-29
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionCandesartan 16mg; Amlodipine 5mg; Amlodipine 10mg
    PhasePhase 3
    Registry statusCompleted